Emerald Advisers LLC Has $15.51 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Emerald Advisers LLC boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 129.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 456,202 shares of the biopharmaceutical company's stock after acquiring an additional 257,773 shares during the quarter. Emerald Advisers LLC owned about 0.69% of Celldex Therapeutics worth $15,506,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Celldex Therapeutics during the 2nd quarter worth about $76,000. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics during the 1st quarter worth about $147,000. CANADA LIFE ASSURANCE Co raised its holdings in Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock worth $192,000 after buying an additional 955 shares during the period. Ameritas Investment Partners Inc. raised its holdings in Celldex Therapeutics by 34.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company's stock worth $260,000 after buying an additional 1,582 shares during the period. Finally, Los Angeles Capital Management LLC raised its holdings in Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock worth $273,000 after buying an additional 638 shares during the period.

Wall Street Analyst Weigh In

CLDX has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Monday, October 28th. Wells Fargo & Company raised Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 26th. The Goldman Sachs Group started coverage on Celldex Therapeutics in a research note on Monday, September 30th. They set a "neutral" rating and a $45.00 target price on the stock. Wolfe Research cut Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. Finally, Citigroup started coverage on Celldex Therapeutics in a research note on Monday, October 7th. They set a "buy" rating and a $70.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Celldex Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $62.25.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX traded down $0.38 during trading hours on Friday, hitting $25.68. The stock had a trading volume of 1,128,081 shares, compared to its average volume of 881,315. The company has a market capitalization of $1.70 billion, a P/E ratio of -9.37 and a beta of 1.60. The firm's 50-day moving average price is $34.89 and its two-hundred day moving average price is $36.21. Celldex Therapeutics, Inc. has a 52 week low of $23.72 and a 52 week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. The business had revenue of $2.50 million during the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. As a group, analysts expect that Celldex Therapeutics, Inc. will post -2.5 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.